Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer

The humanised anti-epidermal growth factor receptor (EGFR) monoclonal antibody matuzumab (formerly EMD 72000) is active against pancreatic cancer in preclinical studies. This phase I study assessed the safety and potential benefit of combined treatment with matuzumab and standard-dose gemcitabine. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Graeven, U, Kremer, B, Südhoff, Th, Killing, B, Rojo, F, Weber, D, Tillner, J, ünal, C, Schmiegel, W
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361405/
https://www.ncbi.nlm.nih.gov/pubmed/16622465
http://dx.doi.org/10.1038/sj.bjc.6603083

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361405/
https://www.ncbi.nlm.nih.gov/pubmed/16622465
http://dx.doi.org/10.1038/sj.bjc.6603083

Ejemplares similares